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Abstract: 
Acute on chronic liver failure (ACLF) is a culmination of chronic liver disease and extra-hepatic 
organ failures, which is associated with a high short-term mortality and immense healthcare 
expenditure. There are varying definitions for organ failures and ACLF in Europe, North America 
and Asia. These differing definitions need to be reconciled to enhance progress in the field. The 
pathogenesis of ACLF is multi-factorial and related to interactions between the immuno-
inflammatory system, microbiota and the precipitating factors. Individual organ failures related to 
the kidney, brain, lungs and circulation have cumulative adverse effects on mortality and are 
often complicated or precipitated by infections. Strategies to prevent and rapidly treat these 
organ failures are paramount in improving survival. With the aging population and paucity of 
organs for liver transplant, the prognosis of ACLF patients is poor, highlighting the need for 
novel therapeutic strategies. The role of liver transplant in ACLF is evolving and needs further 
investigation across large consortia. A role for early palliative care and management of frailty as 
approaches to alleviate disease burden and improve patient-reported outcomes is being 
increasingly recognized. Conclusion: ACLF is a clinically relevant syndrome that is epidemic 
worldwide and which requires a dedicated multi-national approach focused on prognostication 
and management. Investigations are underway worldwide to get ACLF ready for prime time.
This article is protected by copyright. All rights reserved.
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Compensated cirrhosis with >90% 1-year survival can transition into the decompensated stage 
with the onset of jaundice, ascites, variceal bleeding and hepatic encephalopathy (HE) (1)Acute 
on chronic liver failure (ACLF) is associated with rapid deterioration of liver function leading to 
liver failure, multiple extra-hepatic organ failures and high short-term mortality (2). Even if 
patients survive the acute insult, they may never return to their pre-episode functional state (3). 
The term "acute decompensation" has been used to characterize ascites, gastrointestinal 
bleeding, hepatic encephalopathy or infections without organ failure(4). There are several gaps 
in knowledge surrounding ACLF, which will be highlighted in this review. 
The prevalence of ACLF is difficult to assess due to varying regional definitions (5). ACLF, once 
thought to occur only in decompensated cirrhosis, has been recognized even in chronic liver 
disease without cirrhosis (5). ACLF occurs in approximately 10-30% of hospitalized cirrhotic 
patients (6-8). Because of its acuity, patients are frequently admitted into the intensive care unit 
(ICU), and every effort is made to stabilize these patients for liver transplantation (LT). This 
drives healthcare costs(9). Despite this intensive management, ACLF is associated with 
substantial morbidity and mortality. Because curative LT is only available to <10% of cirrhotic 
patients each year and ACLF patients are often delisted, the morbidity and mortality rates 
remain high, especially with an increasing number of organ failures (10).  
Gap:  
- True cost and burden of ACLF worldwide 
 
Definition of ACLF  
ACLF is characterized by rapid progression in liver injury culminating in multiple organ failures 
and possible mortality (5).  Distinction should be made between definition, diagnosis, and 
prognostic criteria for ACLF. Defining a disease requires demonstration of a distinct 
pathophysiology, and a confirmatory diagnostic sign, symptom, or test.  The current 
disagreements between the various definitions are largely because criteria used (ascites and 
This article is protected by copyright. All rights reserved.
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jaundice in the Asian-Pacific “definition”; organ failure in European and North American 
“definitions”) are diagnostic or prognostic criteria and not defining criteria (6, 8, 11, 12).   There 
are currently three widely used definitions of ACLF. Among these definitions, there are 
commonalities, such as high mortality, but also significant differences that give the impression 
that ACLF is not the same disease worldwide (tables 1 and 2).  Lack of standardization in 
definitions is probably related to variability in precipitating events and underlying liver disease.  
For example, in the West, bacterial infection is a common precipitating event whereas in the 
East, both hepatitis B and alcoholic hepatitis are considered precipitating events.  The definition 
of organ failures is also variable (table 3). To arrive at a universally acceptable definition, the 
World Gastroenterology Organization (WGO) proposed a working definition. ACLF was defined 
as “a syndrome in patients with chronic liver disease with or without previously diagnosed 
cirrhosis, characterized by acute hepatic decompensation resulting in liver failure (jaundice and 
prolongation of the international normalized ratio or INR) and one or more extrahepatic organ 
failures, associated with increased mortality up to three months” (5).  The WGO definition was 
proposed to narrow down the group of patients in whom data were to be collected, so that 
ultimately the syndrome could be better defined.  Accordingly, when sufficient data are 
collected, ACLF should be defined with the following qualifications:  
1. Distinguishable from chronic liver disease, compensated cirrhosis and traditional    
decompensated cirrhosis. 
2. A distinct pathophysiology. 
3. Identification of a diagnostic sign, symptom, or confirmatory test.  
4. The diagnosis of ACLF will warrant management change. 
The duration of “acute” is also important.  Data on ACLF in patients with cirrhosis who have 
undergone surgery where the timing of the precipitating event is certain and the course 
postoperatively closely monitored, the increased risk of mortality is for a period of 12 weeks.  
Therefore, the duration of the ACLF “event” should be 12 weeks.  Until such time that a 
This article is protected by copyright. All rights reserved.
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validated definition is available, we propose a generic definition of ACLF, namely that “ACLF is 
a condition in patients with underlying chronic liver disease with or without cirrhosis that is 
associated with mortality within 3 months in the absence of treatment of the underlying liver 
disease, liver support, or liver transplantation”. Examples of ACLF in patients with underlying 
cirrhosis include Wilson disease and alcoholic hepatitis. Examples of ACLF in chronic liver 
disease without cirrhosis include reactivation of chronic hepatitis B, alcoholic hepatitis, and 
either acute viral hepatitis or drug-induced liver injury in the background of NAFLD. 
It is also important to distinguish diagnostic criteria from prognostic criteria.  Diagnostic criteria 
should be such that ACLF is recognized early enough that it can be reversed by appropriate 
management. The Asian-Pacific “definition” of ACLF is associated with a high 28-day mortality 
has merit in terms of diagnostic criteria(12). The criteria are sensitive but not specific for 
diagnosis of ACLF. Current European and North American “definitions” include scores of 
multiple organ failure; such scores reflect or describe the dying process (8, 11).  These scores 
are more specific for mortality within 14 days but are not sensitive beyond that period.  
Therefore, using multiple organ failures as diagnostic criteria may not allow early intervention. 
Organ failure scores should preferably be used to exclude patients from studies or to define 
futility in treatment. The term "acute decompensation" has been used to characterize ascites, 
gastrointestinal bleeding, hepatic encephalopathy or infections without organ failure(4) 
Prognosis is the art for telling disease course and such scores should help select specific 
therapies: when is ICU care sufficient; which patient benefits from regenerative therapy or liver 
support devices; who requires early LT; and when treatment is futile. Multiple prognostic scores 
have been used including the Model for end-stage liver disease (MELD) score, chronic liver 
failure-sequential organ failure assessment (CLIF-SOFA) score, acute physiology and chronic 
health evaluation (APACHE) score and the North American Consortium for the study of end-
stage liver disease (NACSELD) score.  None of these scores have consistently demonstrated a 
This article is protected by copyright. All rights reserved.
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‘c’ statistic greater than 0.8, which is the accepted threshold for an excellent model. ACLF-
specific prognostic scores need to be developed. 
Gaps:  
- Uniform definition worldwide for natural history studies and treatment trials 
- Homogenizing and distinguishing definition, diagnostic criteria and prognostic criteria for 
ACLF. 
- Infections as a consequence or precipitant of ACLF? 
- Contrasting ACLF associated with compensated vs. decompensated cirrhosis vs chronic 
liver disease without cirrhosis 
- Diagnosing ACLF early enough to allow interventions that can reverse disease course 
 
 Pathogenesis of ACLF 
Mechanistic features that differentiate ACLF from traditional acute decompensation (AD) 
Compared to healthy subjects, patients with traditional AD (previously called ‘mere’ AD) exhibit 
features of systemic circulatory dysfunction (SCD), and systemic inflammation, and these 
become much more pronounced in patients with ACLF(13). Excessive systemic inflammation 
can cause ‘intense’ SCD and subsequent low tissue perfusion pressure resulting in organ 
failure. (14). However, the strength of association of ACLF with excessive systemic 
inflammation is significantly higher than with ‘intense’ SCD(13). These findings suggest that 
systemic inflammation can drive ACLF, at least in part, independently of SCD (and tissue 
perfusion). Future research measuring systemic inflammatory markers could help define 
signatures to improve our understanding of inflammation in ACLF (primary prophylaxis).and 
inform preventative strategies. 
Mechanisms of Inflammation: Environmental factors (bacterial infection, excessive alcohol use) 
are the most common identified triggers for inflammation in ACLF(8). Infection by viable bacteria 
(Figure 1) can induce inflammation via two classes of molecules: pathogen-associated 
This article is protected by copyright. All rights reserved.
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molecular patterns (PAMPs) and virulence factors (Figure S1) (15). PAMPs are recognized by 
innate pattern recognition receptors (PRRs), a process called structural feature recognition (15). 
Virulence factors are indirectly recognized by PRRs via a process called functional feature 
recognition (Figure S1) (15). Both processes result in the production of inflammatory molecules 
(Figure S2A and S2B). The inflammatory response to bacteria can be excessive and cause 
tissue damage, which causes the release of damage-associated molecular patterns (DAMPs). 
DAMP recognition by specific receptors perpetuates or accentuates inflammation triggered by 
bacterial inducers (Figure S1, S2A-B) (15). Patients with infection-related ACLF exhibit a ‘storm’ 
of inflammatory cytokines (13).  
Both chronic alcohol use and binge have substantial immunosuppressive effects that weaken 
the already impaired host immune responses in cirrhosis, and increase the risk of infection (16). 
Excessive alcohol use has at least two other major effects; first, alcohol binge results in a multi-
factorial “leaky gut”, resulting in translocation of bacterial PAMPs (such as lipopolysaccharide 
(endotoxin), CpG DNA), but not viable bacteria (17), which stimulate liver inflammation (Figure 
1). Second, alcohol results in release of hepatic DAMPs such as uric acid and ATP that elicit 
NLRP3 inflammasome formation (18) to produce mature interleukin (IL)-1β (Figure S2B). This 
cytokine up-regulates other pro-inflammatory cytokines, sensitizes hepatocytes to other insults, 
promotes liver fibrosis and inhibits liver regeneration (19, 20). NLRP3 formation can cause 
pyroptosis, a form of programmed cell death (Figure S2B). The diseased liver can contribute to 
systemic inflammation by two mechanisms: dying hepatic cells release pro-inflammatory 
DAMPs (Figure S2) and liver inflammation can result in cytokine/chemokine spillover to the 
blood (Figure 2). In other words, in the context of severe alcoholic hepatitis, liver inflammation 
may contribute to systemic inflammation and subsequent multi-organ failure. 
Precipitating factors: Bacterial infection is the most common precipitating factor of AD. However, 
for a given infection, the reasons why some patients develop infection-related ACLF but not 
others are poorly understood. Differences in severity may be related to differences in 
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environmental factors (characteristics of infecting bacteria, alcoholic binge), host non-genetic 
factors (age), and genetic factors, increasing predisposition to develop infection (21-23). 
Similarly, in alcohol misuse, the reasons why some develop ACLF but not others are unclear 
(18, 24). Moreover, a substantial proportion of ACLF patients do not have any identifiable 
precipitating event (8). In these cases, ACLF might result from bacterial or fungal infections that 
have gone undetected, unrecognized drug-induced liver injury, or subclinical intestinal 
translocation of bacterial PAMPs and increased DAMP release. 
Immunodeficiency: It has been hypothesized as a contributor to development of nosocomial 
infections and ACLF(21, 25, 26). However, the blood immune cell subset frequencies, immune 
cell-surface protein expression and transcriptomic signatures have not yet been systematically 
investigated in ACLF. Studies have demonstrated changes in PGE2 and higher subset of 
monocytes overexpressing surface tyrosine-protein kinase Mer (encoded by MERTK)(27, 28). 
Improving our knowledge of immune cell subsets exhibiting features of immune suppression 
should lead to identify targets for new therapies aiming to prevent nosocomial infections and 
subsequent patients’ worsening (secondary prophylaxis).  
Failed tolerance: Infection is associated with two injury mechanisms: first, the immune response 
to infection can be excessive and cause tissue damage; second, infective organisms can 
directly damage tissues(29). The host can reduce this through tissue-intrinsic mechanisms (i.e., 
tolerance or endurance mechanisms) and it is suggested that disease severity could be related 
to failed disease tolerance(30). Among patients with ACLF, for any given level of systemic 
inflammation, patients with prior episodes of decompensation of liver disease have a lower risk 
of death than those without prior episodes(8), suggesting that the former, but not the latter, have 
developed protective tolerance mechanisms.  
Microbiome-host interactions: Cirrhotic patients with/without alcohol misuse have alterations in 
their gut microbiome and intestinal barrier, which correlates with disease severity (31). However, 
This article is protected by copyright. All rights reserved.
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the interactions between the alterations in the intestinal barrier and gut dysbiosis are poorly 
understood (2, 31, 32). Microbiota in sites other than the gut also needs to be explored.  
Role of tissue-resident immune cells: In non-cirrhotic conditions, it has been shown that 
macrophages residing in an injured tissue secrete cytokines and chemokines that attract and 
activate leukocytes with the objective of restoring tissue homeostasis (33). Cytokine spillover 
from damaged tissues might contribute to high systemic cytokine and chemokine levels in 
ACLF, but this needs to be investigated systematically.  
Gaps: 
- Unclear why some patients but not others develop ACLF 
- Absence of precipitating factors in a major proportion of patients 
- Role of microbiota and tissue-resident immune cells is unclear  
 
Individual organ failures and their management  
ACLF is primarily characterized by extra-hepatic organ failures, the specific definitions of which 
vary between regions. However, most definitions of ACLF are associated with failures of the 
renal, brain, respiratory and circulatory systems (8, 11, 12). The only consistent definition is of 
brain failure defined as Grade 3-4 HE. 
Respiratory complications are broadly categorized into acute complications (e.g. the acute 
respiratory distress syndrome, pneumonia, or pulmonary edema) and those which are directly 
associated with liver disease (e.g. hepatopulmonary syndrome and portopulmonary 
hypertension). Previous studies have demonstrated that patients who require mechanical 
ventilation have high rates of mortality (6, 8, 11). However, this is more related to the severity of 
underlying liver disease and not a requirement for mechanical ventilation  (34). Currently, there 
is no evidence to support alternative strategies for management of respiratory failure in cirrhotic 
patients compared to other critically ill patients and typical recommendations are for lung 
protective ventilation strategies using low tidal volumes (35, 36). 
This article is protected by copyright. All rights reserved.
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Circulatory disorders are superimposed on the typical cirrhotic hemodynamic state of a 
hyperdynamic circulation with high cardiac output and low systemic vascular resistance (37). 
Additional structural and functional cardiac abnormalities (cirrhotic cardiomyopathy) occur in 
approximately 40-50% cirrhotic patients (38). Whereas this could support end-organ perfusion in 
compensated patients, tissue perfusion may become inadequate in patients with ACLF with 
their worsening systemic hypotension, thereby requiring hemodynamic support. Assessment of 
volume status and cardiovascular function can be particularly challenging in the cirrhotic patient 
due to significant volume overload. The optimal method for assessing both volume and 
hemodynamic status has yet to be determined. Dynamic measures of cardiovascular function 
such as bedside echocardiography, and in appropriate situations, use of pulmonary artery 
catheters may guide both fluid and pharmacologic resuscitation end-points (39). 
Renal complications range from acute kidney injury (AKI) to acute-on-chronic kidney failure and 
finally the need for renal replacement therapy. AKI, defined as an increase in serum creatinine 
by ≥0.3mg/dL in <48 hours, or a 50% increase from a stable baseline within the past 3 months 
(40), occurs in about 20% of all hospitalized cirrhotics (41). Therefore, renal failure, a severe 
expression of AKI, is also the most common organ failure in patients with ACLF, with type 1 
hepatorenal syndrome (HRS1) as the more severe prototype. The precipitating event for the 
renal failure in ACLF may be related to infection, hypovolemia, or structural renal damage. The 
pathogenesis of renal failure in ACLF is due to a combination of severe inflammation and 
systemic hemodynamic instability. When compared to patients with AD, AKI events in patients 
with ACLF are more likely to be associated with structural renal damage, be prolonged and 
progress to a more severe stage of renal dysfunction (42). Therefore, patients who have AKI 
with ACLF are more likely to require renal replacement therapy, and have less AKI resolution, 
associated with higher mortality, even after recovery (43). Volume expansion, preferably using 
colloid solutions, is the first step in the management. Albumin is the most commonly used due to 
its oncotic and non-oncotic properties (44). Once structural disease has been excluded, 
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treatment should be started as soon as possible, as a lower pre-treatment serum creatinine is a 
consistent predictor of response to vasoconstrictor therapy (45). A combination of albumin and 
vasoconstrictors (terlipressin or norepinephrine), is the mainstay of HRS1 treatment. Although 
midodrine, octreotide and albumin are inferior to terlipressin and albumin (46) for HRS1, a short 
course of the combination may be given if terlipressin is not available. The role of dialysis is 
debated, but in most practices, is only offered to potential LT candidates (6, 39). 
Brain failure is defined as grade 3 or 4 HE. Two large studies determined that HE with ACLF 
conferred a worse prognosis compared to HE without ACLF (47, 48). In the North American 
study, grade 3-4 HE with >2 extra-hepatic organ failures had the highest 30-day mortality. 
Grade 3-4 HE was associated with 30-day mortality independent of other organ failures, 
indicating that brain failure is an important independent prognostic factor (48). HE in cirrhosis is 
caused by a multitude of factors associated with hyperammonemia and systemic inflammation 
(49). However, cirrhotic patients are also susceptible to mental status changes from several 
other causes including medications, alcohol intoxication/withdrawal, intra-cerebral bleeding, 
strokes, and sepsis-associated encephalopathy (50). Progression of HE from lower grades to 
grade 3-4 should be prevented, with a low threshold for instituting airway protection measures. 
The four prongs of treatment of suspected HE or altered mental status in cirrhosis are (i) 
confirmation of HE by ruling out other causes, (ii) standard of care of the unconscious patient 
with airway protection and early transfer to a monitored unit, (iii) management of precipitating 
factors, without which the mental status will not recover, and (iv) empiric HE treatment using 
first-line lactulose and other treatments as available (50). In patients who are not responding to 
the above measures (persistent HE), reconsideration of the diagnosis of HE, continuing to look 
for undiscovered precipitating factors and potentially embolizing spontaneous porto-systemic 
shunts in those with a low MELD score may be further options (51). Brain dysfunction impacts 
end-of-life decision-making and candidacy for LT (37, 52).  
Management of Infection in an effort to prevent ACLF: Infections are one of the most important 
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precipitants of ACLF based on Western definitions (37, 53). With improving survival of variceal 
bleeding, HE and infections have become the leading reasons for hospitalization and 
readmission in cirrhotic patients (54). Recently, the bacteriology of infections has shifted, with 
the emergence of a greater proportion of gram-positive and drug-resistant organisms (21). In 
the absence of rapid infection control there is the risk of organ failure. Nosocomial and second 
infections are reliably associated with the development of ACLF and their prevention may avoid 
ACLF(21, 53). There is also an emergence of fungal infections, which most often arise as a 
result of antibiotic use and following bacterial infections (55). The role of infections in ACLF has 
been debated with the Asian-Pacific definition excluding infected patients, unlike the Western 
definitions (5, 6, 12). Regardless of the inclusion as a precipitant or a result of ACLF, infections 
are a prime target to improve the prognosis. 
Gaps:  
- Differing definitions of organ failures 
- Changing profile of infections  
- Few treatments are directed towards the liver itself  
 
Changing face of cirrhosis, ACLF and outcome management 
The role of extracorporeal liver support in the treatment of ACLF has been explored, despite 
heterogeneous definitions. Although an early study showed promise (56), studies with molecular 
adsorbent recirculating system (57) and PROMETHEUS (58) system failed to show any 
improvement in survival. Therefore, the status of these costly interventions for ACLF is unclear.  
The status of LT in ACLF remains undefined (Table 4). Three studies from Europe reported an 
acceptable 1-year post-LT survival rate for ACLF patients ranging from 75 to 87% (37, 59, 60). 
Post-OLT course of ACLF is currently not predictable. Small series question the value of 
transplanting these patients, with 1-year post-LT survival rate as low as 43-46% (61, 62). 
Furthermore, post-LT complications of ACLF patients are associated with longer ICU and 
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hospital stays compared to patients without ACLF. Infectious, renal, pulmonary and neurological 
complications are the main post-LT events. The liver allocation process in the United States is 
based on MELD score and therefore not uncommonly, patients with ACLF are highly 
competitive,  yet, associated respiratory and circulatory failures may contraindicate LT because 
of the known poor outcomes in such cases. In the multi-center study conducted by the 
NACSELD, infections were a major cause for delisting (52). Within 6 months, 42% of patients 
were de-listed with subsequent poor outcomes, while those transplanted did well. Those who 
were delisted or died had the highest proportion of 3 or 4 organ failures at hospitalization versus 
those listed or subsequently. 
An analysis of United Network for Organ Sharing data from 2002 to 2013 noted a significant 
interaction between MELD score and hospitalization status on post-LT mortality(63). This 
interaction was most pronounced in patients with MELD score of <25 transplanted from an ICU, 
whose adjusted predicted 3-, 6-, and 12-month post-LT mortality approximated those of with a 
MELD of 30. Compared to hospitalized MELD 30–34 patients, those with a MELD≥ 35 in an ICU 
had significantly higher post-LT mortality, suggesting that transplanting patients in the ICU, as is 
the case for most ACLF patients, is associated with suboptimal outcomes and should be 
considered carefully. In another study which used an increase in MELD score by ≥5 within a 
month as the definition of ACLF, the survival and renal outcomes in ACLF LT recipients were 
similar to those without ACLF(64).   
One critical  factor to be considered is that the aging cirrhosis population, which could worsen 
the prognosis with ACLF development because the combination of aging and aging-related co-
morbidities (e.g. diabetes, sarcopenia, coronary artery disease) may synergize with negative 
outcomes. Quantification of debility in these patients for LT eligibility is important. Researchers 
in the field of aging have operationalized older adults’ physiologic reserve with a number of tools 
to measure the concept of frailty – the term referring to a state of decreased physiologic reserve 
and increased vulnerability to health stressors (65). Well-defined frailty tools such as the Fried 
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Frailty Index and Clinical Frailty Scale have been applied to non-geriatric cirrhotic patients, with 
strong associations between frailty and important outcomes including hospitalizations and 
mortality (66, 67). The development of the Liver Frailty Index, consisting of 3 performance-
based measures – grip strength, chair stands, and balance testing – improves the ability of 
MELD-Na to predict mortality in patients awaiting LT (68).  Objective assessment of frailty 
before transplant helps to anchor expectations for recovery of frailty post-LT, especially for older 
patients with ACLF.  
The symptom burden in cirrhosis, especially in those with ACLF, is akin to advanced 
malignancy, making this an important population for palliative management (69). Although often 
misinterpreted as being end-of-life-care, palliative care has relevance at all stages of cirrhosis 
and undoubtedly in patients with ACLF who are not LT candidates. It includes advanced care 
planning and goals of care discussions, symptom control, psychosocial support, assessment of 
functional status and transitions to higher levels of care including hospice. In an ideal setting, 
palliative care principles would first be integrated alongside continued disease-modifying 
therapy, with the patient in a stable outpatient setting.  A focus on transitions of care is also 
important to standardize care between levels of practitioners.  
Gaps:  
- Role of liver assist devices in question 
- High variability in offering transplant – are MELD driven criteria applicable in these 
patients? 
- Selection of appropriate candidates and timing of liver transplant 
- Criteria for delisting of patients, including cut-off for objective metrics of frailty 
- Inadequate accounting for frailty and co-morbid conditions 
- Limited uptake of palliative care,  
Future directions: 
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There are several steps that remain to make ACLF ready for prime time (Table 5). There is 
need for consensus criteria to define and diagnose ACLF, assess severity of liver and other 
organ failures, and initiate standard management protocols.  Variability in management might 
result in variable outcomes in patients with identical severity of ACLF. Thus, there is a need for 
universally accepted management protocols. The final definition of ACLF will likely include an 
assessment of chronic liver disease, a marker of the inflammatory response, and a biomarker 
that is a surrogate for early onset of organ failure.  Such a definition requires identification of a 
distinct pathophysiology that is likely to involve inflammation and the immune system. ACLF 
remains an entity, which has greatly increased in visibility and there has been substantial 
progress in characterizing and managing it. Its readiness for prime time has improved greatly 
and steps to make that a reality are being actively investigated. 
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Figure Legends 
Figure 1. Potential consequences of bacterial translocation in cirrhosis  
Cirrhosis is associated with gut dysbiosis. Viable Gram-negative bacteria can 
translocate from the intestinal lumen to blood via a transcellular pathway which is poorly 
known. Translocated bacteria can reach ascites via systemic circulation and cause 
spontaneous bacterial peritonitis (SBP). Bacterial by-products such as pathogen-
associated molecular patterns (PAMPs) can translocate via a paracellular route (a 
process that is favored by intestinal tight junction disruption). Then, PAMPs can reach 
the liver and here be recognized by pattern-recognition receptors (PRRs) resulting in 
liver inflammation. 
Figure 2. A scenario for a role of liver necrosis and inflammation in extra-hepatic 
multi-organ failure, in the context of severe alcoholic hepatitis 
Severe alcoholic hepatitis is associated with cell death and inflammation in the liver. 
Cell death can result in the release of damage-associated molecular patterns (DAMPs) 
that reach systemic circulation and cause remote inflammation in tissues that express 
their cognate receptors. Liver inflammation can result in cytokine/chemokine spillover to 
blood, which brings them to extrahepatic organs where they cause inflammation. 
Therefore, in severe alcoholic hepatitis, molecules produced by the liver can cause 
remote extrahepatic organ inflammation and subsequent dysfunction/failure. Pathogen-
associated molecular patterns that have translocated from the intestinal lumen to blood 
(see Figure 1) may also contribute to inflammation of extra-hepatic organs (not shown). 
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Table 1:   Comparison of the Definitions for Acute-on-Chronic Liver Failure (ACLF) 
 
 
 
Asian Pacific Association for the 
Study of Liver (APASL)  
European Association for the Study 
of Liver-Chronic Failure (EASL-CLIF) 
North American Consortium for 
Study of End-stage Liver Disease 
(NACSELD) 
World 
Gastroenterology 
Organization 
(WGO Proposal) 
Derivation 
 
Consensus and observational Prospective, observational study Prospective study in patients with 
Cirrhosis and infection 
Consensus 
Patient 
Population 
Inclusion 
Chronic liver disease 
 
Compensated cirrhosis 
Compensated and decompensated 
cirrhosis 
Decompensated cirrhosis by 
implication 
Non-cirrhotic 
chronic liver 
disease; 
compensated and 
decompensated 
cirrhosis 
Exclusion Infection, prior hepatic decompensation HCC outside Milan criteria 
 
HIV infection 
 
Significant comorbidity 
HIV infection 
 
Prior organ transplantation 
 
Untreated malignancies 
Not stated 
Severity Score Liver failure defined as jaundice (serum 
bilirubin ≥5 mg/dL) and coagulopathy 
(INR of ≥1.5 or prothrombin activity of 
≤40%).  
 
Ascites or encephalopathy develops 
within 4 weeks. 
Hepatic and extrahepatic organ failure. Extrahepatic organ failure Not Stated 
Comments Diagnosis can be made early enough for 
intervention to alter disease course. 
 
Diagnosis is sensitive but not specific for 
early mortality 
Diagnosis of ACLF may be made too 
late to impact disease outcome. 
Diagnosis of ACLF may be made too 
late to impact disease outcome. 
Working 
definition for 
data collection to 
ultimately arrive 
at a validated 
definition 
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ACLF: Acute-on-chronic liver failure; HCC: hepatocellular carcinoma; HIV: human immunodeficiency virus; INR: International 
normalized ratio
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Table 2:   Other areas of difference among Definitions of ACLF 
 
 Duration of Event Underlying Liver 
Disease 
Common Precipitating Events Requirement for 
Diagnosis of ACLF 
APASL 4 weeks Non-cirrhotic chronic 
liver disease. 
 
Compensated cirrhosis 
Reactivation hepatitis B 
 
Superimposed hepatitis E 
 
Alcoholic hepatitis 
Ascites, hepatic 
encephalopathy 
EASL-CLIF 4 weeks Compensated and 
decompensated 
cirrhosis 
Alcoholic hepatitis 
Bacterial infections 
 
Unknown in ≥40% 
Organ failure (hepatic 
failure not essential 
for diagnosis) 
NACSELD 30 days Not specified, but by 
implication all patients 
had decompensated 
cirrhosis 
Not specified, but only patients 
with infection included. 
 
Extrahepatic organ 
failure 
WGO 3 months Chronic liver disease 
with or without 
cirrhosis. 
 
Both compensated 
cirrhosis and 
decompensated 
cirrhosis included 
Alcoholic hepatitis  
Infection                  (West) 
 
Reactivation 
hepatitis B 
 
Superimposed  
hepatitis E 
Alcoholic hepatitis 
Hepatic and 
extrahepatic organ 
failure 
  
Asian Pacific Association for the Study of Liver (APASL), European Association for the Study of Liver-Chronic Failure (EASL-CLIF), North American 
Consortium for Study of End-stage Liver Disease (NACSELD), World Gastroenterology Organization (WGO Proposal) 
East 
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 Table 3:  Variability in Definitions of Organ Failure* 
Type of Organ 
Failure 
APASL Organ Failure Definitions EASL-CLIF Organ Failure 
Definitions 
NACSELD Organ Failure 
Definition 
Liver Total bilirubin ≥5 mg/dL and INR ≥1.5 Bilirubin level >12 mg/dL       - 
Kidney Acute Kidney Injury Network criteria Creatinine level of ≥2.0 mg/dL 
or renal replacement therapy 
Need for dialysis or other 
forms of renal replacement 
therapy 
Brain West-Haven hepatic encephalopathy grade 3-4 West-Haven hepatic 
encephalopathy grade 3-4 
West-Haven hepatic 
encephalopathy grade 3-4 
Coagulation INR ≥ 1.5 INR ≥ 2.5 -  
Circulation  Use of vasopressor (terlipressin 
and/or catecholamines) 
Presence of shock defined by 
mean arterial pressure <60 mm 
Hg or a reduction of 40 mm Hg 
in systolic blood pressure from 
baseline, despite adequate 
fluid resuscitation and cardiac 
output 
Respiration  Pa02/Fi0 2 of ≤200 or Sp02/Fi02 
of ≤214 or need for mechanical 
ventilation [Note: Accepted 
ratio is  ≤300 for ALI or ≤200 for 
ARDS] 
Need for mechanical 
ventilation 
ALI, Acute Lung injury, ARDS, Adult respiratory distress syndrome, Fi02, fraction of inspired oxygen; INR, international normalized 
ratio, Pa02, partial pressure of arterial oxygen; Sp02; pulse oximetric saturation. * WGO did not define organ failures 
Asian Pacific Association for the Study of Liver (APASL), European Association for the Study of Liver-Chronic Liver Failure (EASL-CLIF), North 
American Consortium for Study of End-stage Liver Disease (NACSELD), World Gastroenterology Organization (WGO Proposal) 
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Table 4: Liver transplant and ACLF 
First Author (reference 
number) 
Experience Criteria for ACLF Survival Notes 
Gustot et al. (37) CANONIC
 
CLIF criteria 80.9 v 10% (180 days) Tx day 3-7, favors LT 
Finkenstedt et al. (60) Innsbruck
 
APASL criteria 87 and 82% (1 and 5 
years) 
Favors LT  
Artru et al. (59) Lille/P Brousse/Montpellier
 
CLIF-OF 83.9 vs 7.9% 1y 
survival 
Favors LT, ACLF pts 
have high 
complication rates 
Reddy et al. (52) NACSELD
 
NACSELD criteria 95% vs <10% 
(compared with those 
delisted due to ACLF) 
Favors LT 
Bahirwani et al. (64) University of Pennsylvania MELD score increase >5 
within 4 weeks 
74.5% vs 83.4% 
unadjusted 
After adjustment, 
ACLF did not appear 
to affect post-LT 
survival 
Levesque et al. (62) 
 
Montpellier/Henri Mondor
 
EASL-CLIF 90% 90 day survival Does not favor LT 
Umgelter et al. (61) Munich
 
MELD/SOFA/APACHE 46% 1y survival Shorter ICU stay and 
higher MELD at admit 
favored better survival 
European Association for the Study of Liver-Chronic Failure (EASL-CLIF), North American Consortium for Study of End-stage Liver Disease 
(NACSELD),  model for end-stage liver disease (MELD), treatment (Tx), liver transplant (LT), Intensive care unit (ICU), Acute Physiology And 
Chronic Health Evaluation II (APACHE), Sequential organ failure assessment (SOFA), Acute on chronic liver failure (ACLF).  
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Table 5: Future Directions for ACLF research  
Areas of need in ACLF Specific steps needed to address the gaps 
Burden of ACLF 1. Consortia that also include centers that are not transplant centers. 
2. Education about ACLF beyond academic centers  
Definition  1. Focus on narrowing the differences,  
2. Simplifying definitions to increase generalizability  
3. Focus on separate diagnostic and prognostic markers 
4. Could conventional prognostic scoring systems in ACLF patients perform better if markers of 
systemic inflammation and circulatory dysfunction are included? 
Pathogenesis  1. Research to identify PAMPs and DAMPs as diagnostic biomarkers of the mechanism of ACLF.  
2. Excessive responses to DAMP(s) might also be under control of genetic factors and appropriate 
genome-wide association studies are required 
3. No comprehensive description of the landscape of circulating immune-suppressed cells is 
available in patients with ACLF 
4. Cytokine/chemokine signatures for identification and grading of systemic inflammation are 
required 
5. Changes in microbiota in differing stages of ACLF 
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 ACLF: acute-on-chronic liver failure; DAMP: damage associated molecular pattern; ICU: intensive care unit; PAMP: pathogen 
associated molecular pattern 
Organ failure management 1. Biomarkers should be developed to identify early tissue dysfunction before failure sets in 
2. Should the type of precipitating event (extrahepatic vs intrahepatic) be included in these 
prognostic scores? 
3. Prevention of organ failures is critical 
4. Changes in bacteriology and increasing importance of infections as modulators of ACLF are 
needed 
5. Organ-specific therapies are required 
6. Bridging therapies with liver-assist devices and elucidating the role of liver transplant 
7. Which is the most appropriate time to decide prognosis in ACLF patients (given the dynamic 
course of ACLF)? 
Non-medical approaches for ACLF  
1. Greater multi-disciplinary coordination between palliative care, transplant and inpatient 
hepatology services, 
2. Improved education of trainees, professionals involved in ICU, Infectious disease, liver transplant 
care as well as palliative care professionals 
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